For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Calithera Biosciences, Inc.

USPTO Granted Patents = 30

EPO Patents = 12

Trademarks = 3

Forward Citations = 110

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Jim W Li (14 out of 38 patents)

Lijing Chen (12 out of 16 patents)

Eric Brian Sjogren (11 out of 64 patents)

4. Timothy Friend Stanton (9 out of 11 patents)

5. Roland Joseph Billedeau (8 out of 23 patents)

6. Michael C Van Zandt (8 out of 44 patents)

7. Matthew I Gross (7 out of 7 patents)

8. Francesco Parlati (6 out of 21 patents)

9. Darren Whitehouse (5 out of 18 patents)

10. Susanne M Steggerda (4 out of 5 patents)

11. Guy Laidig (4 out of 4 patents)

12. Bindu Goyal (4 out of 10 patents)

13. Jennifer L Savoy (3 out of 3 patents)

14. Lene Raunkjær Petersen (3 out of 3 patents)

15. Susan D Bromley (3 out of 3 patents)

30 patents: Sort by Forward Citations

1. 11370754 - Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide (2022-06-28),

2. 11352355 - Solid state forms of fused heteroaromatic pyrrolidinones (2022-06-07),

3. 11291674 - Arginase inhibitor combination therapies (2022-04-05),

4. 11208414 - Ectonucleotidase inhibitors and methods of use thereof (2021-12-28),

5. 11078228 - Ectonucleotidase inhibitors and methods of use thereof (2021-08-03),

6. 11034715 - Ectonucleotidase inhibitors and methods of use thereof (2021-06-15),

7. 11021495 - Compositions and methods for inhibiting arginase activity (2021-06-01),

8. 10940148 - Combination therapy with glutaminase inhibitors and immuno-oncology agents (2021-03-09),

9. 10906872 - Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide (2021-02-02),

10. 10905701 - Compositions and methods for inhibiting arginase activity (2021-02-02),

11. 10851118 - Compositions and methods for inhibiting arginase activity (2020-12-01),

12. 10844080 - Compositions and methods for inhibiting arginase activity (2020-11-24),

13. 10793535 - Heterocyclic glutaminase inhibitors (2020-10-06),

14. 10676472 - Crystal forms of glutaminase inhibitors (2020-06-09),

15. 10597411 - Compositions and methods for inhibiting arginase activity (2020-03-24),

Calithera Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other diseases. The company's research and development efforts are centered on developing innovative therapies that target metabolic and tumor signaling pathways. Calithera is committed to making a meaningful difference in the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

30 Patents

#43 in South San Francisco, CA

#2,590 in California

#10,860 in US

#21,192 in the World

South San Francisco, CA, United States of America

Calithera Biosciences, Inc.

Forward Citations = 110

37 inventors:

Jim W Li (14 out of 38 patents)

Lijing Chen (12 out of 16 patents)

Eric Brian Sjogren (11 out of 64 patents)

4. Timothy Friend Stanton (9 out of 11 patents)

5. Roland Joseph Billedeau (8 out of 23 patents)

Please report any incorrect information to support@idiyas.com

Loading…